Target family: P2Y receptors (type: gpcr)
Target: P2Y<sub>11</sub> receptor

Ligand: 2MeSATP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: ADP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: ADPβS (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: AR-C67085 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pEC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: AR-C67085 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pEC50
Reference (Journal): Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors.
Published in: J Mol Cell Cardiol

Ligand: ATP (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.
Published in: Mol Pharmacol

Ligand: ATP (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: ATP (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem

Ligand: ATPγS (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: BzATP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: dATP (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: NAADP (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): NAADP+ is an agonist of the human P2Y11 purinergic receptor.
Published in: Cell Calcium

Ligand: NAD (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes.
Published in: J Biol Chem

Ligand: NF157 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.349999904632568 pKi
Reference (Journal): Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
Published in: J Med Chem

Ligand: NF340 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
Published in: J Pharmacol Exp Ther

Ligand: NF340 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Invited Lectures : Overviews Purinergic signalling: past, present and future.
Published in: Purinergic Signal

Ligand: NF546 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.27 pEC50
Reference (Journal): NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
Published in: J Pharmacol Exp Ther

Ligand: reactive blue-2 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: suramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterization of the human P2Y11 receptor.
Published in: Br J Pharmacol

Ligand: UTP (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5.199999809265137 pEC50
Reference (Journal): Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.
Published in: Mol Pharmacol